Healthcare / BiotechnologyWarsaw
$5.95
+0.33 (+5.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-57.2M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$123M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.3%
↓Gross Margin
N/A
•Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
2.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-31.3M · FCF $-80.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $100.00 | — | $400.00 |
| Net Income | $-31.3M | $-31.3M | $-28.4M | $-15.3M | $-13.6M |
| EBITDA | $-27.5M | $-27.5M | $-24.5M | $-14.0M | $-13.3M |
| EPS | -1.55 | -1.55 | -1.69 | -1.09 | -0.98 |
| Gross Margin | — | — | -4101610.0% | — | -693272.5% |
| Operating Margin | — | — | -32128045.0% | — | -3441074.8% |
| Net Margin | — | — | -28373117.0% | — | -3409079.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.07 | 0.05 | 0.04 |
| Cash Flow | |||||
| Free Cash Flow | $-80.8M | $-80.8M | $-57.2M | $-43.8M | $-32.3M |
| Returns | |||||
| ROE | -30.3% | -30.3% | -28.1% | -12.1% | -9.7% |
| Valuation | |||||
| P/B | 1.16 | 1.16 | 3.34 | 1.71 | 4.04 |
| Growth & Yield | |||||
| EPS Growth | 8.3% | 8.3% | -55.0% | -11.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.69 → -1.55
Residual
-25.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.